Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that predictable routine of Zoom meetings, Skype meetings, and deadlines has returned. Pandemic or no pandemic, the world somehow keeps spinning. So let us embrace the inevitable together with a comforting cup of stimulation and proceed on the journey. Toward that end, here are a few tidbits. Hope your day goes well, and do keep in touch. …

Two Covid-19 vaccine candidates being developed by Pfizer (PFE) and BioNTech (BNTX) received Fast Track designation status from the Food and Drug Administration, Reuters writes. The vaccines are the most advanced of at least four vaccines being assessed by the companies in ongoing trials in the U.S. and Germany. Earlier this month, the companies disclosed that one vaccine, called BNT162b1, showed potential against the virus and was found to be well-tolerated in early-stage human trials. Early data from the German trial of the same vaccine are expected this month.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy